(RTTNews) - BioVie Inc. (BIVI) on Wednesday announced the initiation of patient enrollment in its Phase 2 SUNRISE-PD clinical trial, evaluating bezisterim or NE3107 in patients with early-stage ...
-Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone- -Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON ...
BioVie Inc. presented its SUNRISE-PD trial's patient-centric design at the ATMRD Congress, enhancing access for Parkinson's patients. BioVie Inc. announced that a poster on its SUNRISE-PD Phase 2 ...
BioVie (BIVI) announced that patient enrollment is now open for the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients with ...
Poster displayed from 7:00am Friday June 27 through 2:00pm Sunday June 29 SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design ...
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one ...
CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results